Johnson & Johnson

Research Johnson & Johnson (JNJ) on Bullrun: valuation model: 3.8% undervalued, market cap USD 622.29B, P/E 29.9, dividend yield 2.0%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerJNJ
• ExchangeNYSE
• CountryUnited States
• SectorHealthcare
• IndustryDrug Manufacturers-General
• CurrencyUSD
• Valuation signal3.8% undervalued
• Market capUSD 622.29B
• P/E29.9
• Dividend yield2.0%
• Financial periodFY2025
• RevenueUSD 94.19B
• Revenue growth6.0%
• Net incomeUSD 26.80B
• Free cash flowUSD 19.70B
• Gross margin67.9%

Valuation Snapshot

Bullrun's latest valuation model marks Johnson & Johnson as 3.8% undervalued; latest market cap is USD 622.29B; P/E is 29.9; dividend yield is 2.0%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech.

Frequently asked questions

Is Johnson & Johnson overvalued or undervalued?

Bullrun's valuation model currently marks Johnson & Johnson as 3.8% undervalued.

What is Johnson & Johnson's market cap?

Johnson & Johnson's market capitalization is USD 622.29B.

What is Johnson & Johnson's P/E ratio?

Johnson & Johnson's price-to-earnings (P/E) ratio is 29.9.

Does Johnson & Johnson pay a dividend?

Johnson & Johnson has a dividend yield of 2.0%.

What does Johnson & Johnson do?

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech.